If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUltrasis Plc Regulatory News (ULT)

  • There is currently no data for ULT

Interim Results

4 Apr 2012 07:00

RNS Number : 7157A
Ultrasis PLC
04 April 2012
 



Ultrasis plc

("Ultrasis" or the "Company")

Interim Results for the six months ended 31 January 2012

Ultrasis, the provider of interactive health care services, announces its unaudited financial results for the six months ended 31 January 2012 (the "Interim Results"):

 

• Revenue of £513,000 (2011: £1,437,000) is significantly lower than the prior period due mainly to the sustained pause in spending in our core NHS market whilst the government's Health reforms are being implemented.

 

• Loss before tax of £771,000 (2011: profit before tax of £191,000), reflecting the fall in revenues.

• Administrative expenses of £1,289,000 (2011: £1,227,000): The Company is currently reducing its cost base to better match conservative revenue forecasts for the full year. Accordingly, the Company entered into a consultation period on staff redundancies consequent on restructuring, with some action already implemented.

 

• Cash reserves of £1,421,000 (2011: £2,123,000) have reduced because of the continued hiatus in UK sales revenue in the NHS.

 

• Positively, we continue pursuit of our strategy to diversify into new markets at home and abroad with both "GetFit Wellness" solutions and "Beating the Blues" ("BtB"), in an effort to reduce the Company's reliance on the domestic NHS market.

 

 

For further information contact:

 

Ultrasis plc

Nigel Brabbins, CEO

 

Tel: +44 (0) 20 7535 2050

Strand Hanson Limited

Stuart Faulkner / Liam Buswell

 

Tel: +44 (0) 20 7409 3494

JBP Public Relations

Tel: +44 (0) 11 7907 3400

 Chris Lawrance

 

Statement from Chairman and Chief Executive

 

The economic climate remains very tough and the last six months have been particularly challenging in our core market, the UK's NHS, due to fundamental changes to commissioning arrangements under the Health & Social Care Bill. Whilst a large number of the new Clinical Commissioning Groups ("CCG's") and GP Consortia have been established, they are in a "shadow" form with funding arrangements still to be finalised and have only recently been granted legal authority. This situation and the general pressure across the NHS to avoid expenditure commitments have had a severe adverse impact on the Company's sales in the UK. Accordingly, the Company has taken action to mitigate the impact of declining UK sales.

 

"Beating the Blues" remains a world leading low cost solution for the treatment of anxiety and depression, as evidenced by the choice of countries such as New Zealand, which made BtB available nationally. Already Ultrasis' joint venture with UPMC of Pittsburgh - Usquared Interactive - is gaining traction in the more fertile North American market and we expect to announce more contract gains across a diverse range of new customers in the near future.

 

However, the NHS remains an important area of focus. There continues to be an increasing number of patients visiting GPs with depression and poor mental health. The current structural reorganisation in the NHS has resulted in a pause in revenue but when the new structures, which are designed to focus on efficient deployment of resources, are fully operational we believe that the cost effective solution that "Beating the Blues" offers will have direct economic relevance to our NHS customer.

 

Financial highlights

 

Revenues in the period were £513,000 (2011: £1,437,000), significantly lower than the prior period due to the sustained pause in spending in our core NHS market. Administrative expenses were £1,289,000 (2011: £1,227,000). The loss before tax of £771,000 (2011: profit before tax of £191,000) and the reduced cash reserves of £1,442,000 (2011: £2,123,000) are both reflective of the fall in revenues during the period.

 

Nigel Brabbins Gerald Malone

Chief Executive Non-Executive Chairman

 

 

4 April 2012

CONSOLIDATED statement of comprehensive income for the six months ended 31 January 2012

 

 

Six months ended 31 Jan

Six months

ended 31 Jan

Year ended

31 Jul

Notes

2012

2011

2011

(unaudited)

(unaudited)

(audited)

 

£'000

£'000

£'000

Revenue

513

1,437

2,839

Cost of sales

(14)

(19)

(44)

Gross profit

499

1,418

2,795

Administrative expenses

(1,289)

(1,227)

(2,769)

Operating (loss)/profit

(790)

191

26

Finance costs

(1)

(2)

(15)

Finance income

20

2

6

(Loss)/profit before taxation

(771)

191

17

Taxation

-

(51)

(67)

(Loss)/profit for the period

(771)

140

(50)

Other comprehensive income:

Exchange difference on translation of foreign subsidiaries

5

-

1

 

Total comprehensive income for the year attributable to equity holders of the parent

 

(766)

 

140

 

 

 

(49)

(Loss)/earnings per share

Basic (loss)/earnings per share (p)

2

(0.05)

0.01

(0.003)

Diluted (loss)/earnings per share (p)

2

(0.05)

0.01

(0.003)

 

 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY for the six months ended 31 January 2012

 

Share capital

Share premium

Share option reserve

Capital reduction reserve

Merger reserve

Translation reserve

Retained losses

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000

Balance at

1 August 2010

 

1,508

 

21,302

1,634

6,650

2,324

(7)

(26,654)

6,757

Total comprehensive income for the period

 

-

-

-

-

-

-

140

140

Share based payments

-

-

13

-

-

-

-

13

Balance at

31 January 2011

1,508

 

21,302

1,647

6,650

2,324

(7)

(26,514)

6,910

Balance at

1 August 2010

 

1,508

 

21,302

1,634

6,650

2,324

(7)

(26,654)

6,757

Total comprehensive income for the period

-

-

-

-

-

1

(50)

(49)

Share based payments

-

-

25

-

-

-

-

25

Balance at

31 July 2011

1,508

 

21,302

1,659

6,650

2,324

(6)

(26,704)

6,733

Total comprehensive income for the period

-

-

-

-

-

(5)

(771)

(776)

Share based payments

-

-

13

-

-

-

-

13

Balance at

31 January 2012

1,508

 

21,302

1,672

6,650

2,324

(11)

(27,475)

5,970

 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION as at 31 January 2012

 

 

 

 

31 Jan

 

 

31 Jan

 

 

31 Jul

 

 

2012

2011

2011

 

(unaudited)

(unaudited)

 

(audited)

 

£'000

£'000

£'000

 

 

Non-current assets

 

Intangible assets

2,793

2,715

2,851

 

Plant and equipment

46

47

47

 

Deferred tax assets

1,973

1,998

1,973

 

 

Total non-current assets

4,812

4,760

4,871

 

 

Current assets

 

Inventories

-

13

-

 

Trade and other receivables

484

1,352

1,059

 

Cash and cash equivalents

1,442

2,123

2,368

 

 

Total current assets

1,926

3,488

3,427

 

 

Current liabilities

 

Trade and other payables

(187)

(320)

(682)

 

Deferred revenue

(581)

(1,018)

(883)

 

 

Total current liabilities

(768)

(1,338)

(1,565)

 

 

Net current assets

1,158

2,150

1,862

 

 

Net assets

5,970

6,910

6,733

 

 

 

Equity

 

Share capital

1,508

1,508

1,508

 

Share premium account

21,302

21,302

21,302

 

Share option reserve

1,672

1,647

1,659

 

Other reserves

6,650

6,650

6,650

 

Merger reserve

2,324

2,324

2,324

 

Foreign exchange reserve

(11)

(7)

(6)

 

Retained losses

(27,475)

(26,514)

(26,704)

 

 

 

5,970

6,910

6,733

 

 

CONSOLIDATED CASH FLOW STATEMENT for the six months ended 31 January 2012

 

 

 

Six months ended 31 Jan

Six months ended 31 Jan

Year ended 31 Jul

 

2012

2011

2011

(unaudited)

 

(unaudited)

 

(audited)

 

£'000

£'000

£'000

Cash used in operations

Operating (loss)/profit

(790)

191

26

Share based payments

13

13

25

Depreciation charge

9

11

21

Amortisation of intangible fixed assets

98

88

167

Decrease in inventories

-

-

13

Decrease/(increase) in receivables

575

(613)

(311)

(Decrease)/increase in payables

(797)

72

301

Net cash used in operating activities

(892)

(238)

242

Investing activities

Interest received

2

2

6

Purchases of intangible fixed asset

(39)

(19)

(241)

Purchases of plant and equipment

(14)

(3)

(7)

Net cash used in investing activities

(51)

(20)

(242)

Financing activities

Interest paid

(1)

(2)

(4)

Net cash used in financing activities

(1)

(2)

(4)

Net decrease in cash and cash equivalents

(944)

(260)

(4)

Cash and cash equivalents at beginning of period

2,368

2,383

2,383

Effects of exchange rate changes on the balance of cash held in foreign currencies

18

-

(11)

Cash and cash equivalents at end of period

1,442

2,123

2,368

 

 

NOTES TO THE FINANCIAL INFORMATION for the six months ended 31 January 2012

 

1. Nature of financial information

 

The consolidated interim financial statements of Ultrasis plc (the "Company") comprise the result of the Company and its subsidiaries for the period 1 August 2011 to 31 January 2012. The financial information contained in this interim report does not constitute statutory accounts as defined by section 435 of the Companies Act 2006. The interim financial information is unaudited and incorporates unaudited comparative figures for the interim period 1 August 2010 to 31 January 2011 and extracts from the audited financial statements for the year to 31 July 2011. The financial information for the year ended 31 July 2011 set out in this interim report does not constitute the Company's statutory accounts for that period. The statutory accounts for the year ended 31 July 2011 have been delivered to the Registrar of Companies. The auditors reported on those accounts; their report was unqualified, did not contain a statement under either Section 498 (2) or Section 498 (3) of the Companies Act 2006 and did not include references to any matters to which the auditor drew attention by way of emphasis.

 

The interim financial information has been prepared using International Financial Reporting Standards (IFRS and IFRIC interpretations) issued by the International Accounting Standards Board ("IASB") as adopted for use in the EU, with the exception of IAS 34, which is not required for AIM listed companies. The interim financial information has been prepared on a basis consistent with the accounting policies disclosed in the Annual Report and Accounts for the year ended 31 July 2011.

 

2. Basic and Diluted earnings per share

Pence per share

 

Six months ended

31 Jan 2012

(unaudited)

 

Six months

ended

31 Jan 2011

(unaudited)

Year ended 31 Jul 2011

 

(audited)

Basic and diluted (loss)/earnings per share

(0.05)

0.01

(0.003)

 

The calculation of diluted alternative earnings per share assumes conversion of all potentially dilutive ordinary shares, all of which arise from share options.

 

The calculations of earnings per share are based on the following profits and numbers of shares:

 

Six months ended 31 Jan

Six months ended 31 Jan

Year ended

31 Jul

2012

£'000

2011

£'000

2011

£'000

(unaudited)

(unaudited)

(audited)

(Loss)/profit

(Loss)/profit for the purposes of basic earnings per share, being (loss)/profit for the period attributable to equity shareholders

(766)

140

(50)

 

Number of shares

 

Weighted average number of ordinary shares for the purposes of basic profit per share

1,507,853,258

 

1,507,853,258

 

1,507,853,258

 

Weighted average number of ordinary shares for the purposes of diluted profit per share

1,509,853,258

 

1,509,853,258

 

1,509,853,258

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR ZMGGDGFKGZZM
Date   Source Headline
1st Oct 20137:00 amRNSNew Customer Win
16th Sep 20139:30 amRNSBeating the Blues Research at The White House
13th Sep 20137:00 amRNSBoard Changes
9th Sep 20139:04 amRNSAcquisition & Issue of Equity
6th Sep 20137:00 amRNSDirectorate Change
2nd Sep 20132:50 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSNew corporate website
20th Aug 20137:00 amRNSContract Win
2nd Aug 201311:45 amRNSFurther US Success for Beating the Blues
1st Aug 20135:03 pmRNSIssue of Equity and Directors' Dealings
1st Aug 20137:00 amRNSNew partnership to address NHS market
5th Jul 20131:00 pmRNSIssue of Equity
17th Jun 20137:52 amRNSUltrasis US Joint Venture Success
14th Jun 20137:00 amRNSHolding(s) in Company
7th Jun 20137:00 amRNSDirectorate Change
21st May 20137:00 amRNSStrategic partnership with US Joint Venture
1st May 20133:40 pmRNSIssue of Equity and Block listing update
2nd Apr 201312:00 pmRNSChange of Adviser
20th Mar 20137:00 amRNSInterim Results
14th Feb 20137:00 amRNSCompletion of fundraising and total voting rights
4th Feb 20132:32 pmRNSIssue of Shares under Share Incentive Plan
30th Jan 20133:45 pmRNSResult of AGM
29th Jan 20137:00 amRNSProposed Financing Arrangements & Director Change
7th Jan 20137:00 amRNSAnnual Report & Notice of AGM
16th Nov 20127:00 amRNSFinal Results
5th Nov 20127:00 amRNSFurther Research Success
5th Nov 20127:00 amRNSIssue of Shares & Blocklisting Update
1st Nov 20122:15 pmRNSHolding(s) in Company
1st Nov 20127:00 amRNSNew Contract Win
2nd Aug 20128:10 amRNSCost Control and Share Incentive Plan
31st Jul 20127:00 amRNSNew customer for US Joint Venture
11th Jul 20127:00 amRNSChina Hospital Partnership
12th Jun 20122:28 pmRNSHolding(s) in Company
2nd May 20127:00 amRNSIssue of Shares & Block Listing Update
30th Apr 201211:00 amRNSGrant for BtB US Trials
24th Apr 20129:40 amRNSHolding(s) in Company
4th Apr 20127:00 amRNSInterim Results
7th Feb 201212:45 pmRNSHolding(s) in Company
1st Feb 201212:51 pmRNSIssue of Shares under Share Incentive Plan
27th Jan 20127:00 amRNSResult of AGM
26th Jan 20127:00 amRNSFirst customer for US version of Beating the Blues
25th Jan 20127:00 amRNSHolding(s) in Company
16th Jan 20127:00 amRNSCommencement of Pilot Project
9th Jan 20121:00 pmRNSCanadian Pilot
20th Dec 201111:00 amRNSAnnual Report and Notice of Annual General Meeting
8th Nov 20117:01 amRNSBlocklisting Six Monthly Update
8th Nov 20117:00 amRNSFinal Results
25th Oct 201111:00 amRNSUltrasis launches Share Incentive Plan
10th Oct 20117:00 amRNSNew Partnership
6th Oct 201112:00 pmRNSLaunch of US version of Beating the Blues

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.